2020
Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
Hu JK, Carlson K, Girardi M. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. The Yale Journal Of Biology And Medicine 2020, 93: 41-44. PMID: 32226334, PMCID: PMC7087069.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesLocal immunotherapyIntralesional injectionSide effectsAssociated systemic side effectsSkin-homing T cellsEarly-stage mycosis fungoidesTreatment of MFCases of MFGeneralized side effectsStage mycosis fungoidesT-cell lymphomaSystemic side effectsRecombinant interferon α2bImprovement of diseaseSystemic therapyRecalcitrant lesionsMF patientsTherapeutic optionsMalignant CD4Intramuscular injectionMF lesionsSystemic administrationSubsequent dosing
2018
Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate
Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.Peer-Reviewed Original ResearchMeSH KeywordsAminopterinDose-Response Relationship, DrugFemaleFolic Acid AntagonistsFollow-Up StudiesHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedPrognosisRetrospective StudiesSkin Neoplasms
2010
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 2010, 63: 975-983. PMID: 20888065, DOI: 10.1016/j.jaad.2009.12.052.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaToll-like receptor 9 agonistPF-3512676Receptor 9 agonistT-cell lymphomaSézary syndromeMycosis fungoidesIVa cutaneous T cell lymphomaRefractory cutaneous T-cell lymphomaPhase I dose-escalation studyI dose-escalation studyClass of lymphomasIndex Lesion SeverityClinical response rateCommon adverse eventsPhysician global assessmentPrimary end pointDose-escalation studyPhase I trialWeekly subcutaneous injectionsLimited therapeutic optionsTreatment of patientsEnd of studyStage IBAdverse events